{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-192031","form_type":"8-K","ticker":null,"cik":"0001808865","company_name":"iTeos Therapeutics, Inc.","filed_at":"2025-08-29T23:59:59+00:00","discovered_at":"2026-05-14T18:02:45.066509+00:00","generated_at":"2026-05-17T09:16:25.918373+00:00","sec_items":["2.01","3.01","3.03","5.01","5.02","5.03","9.01"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"iTeos Therapeutics acquired by Concentra Biosciences for $10.047/sh plus CVR","bullets":["Tender offer closed with 72.17% of shares tendered; all conditions satisfied; merger effective Aug 29, 2025.","Shareholders receive $10.047 cash per share plus one non-transferable CVR per share.","CVR entitles holders to 80% of net proceeds from future disposition of specific product candidates (EOS-984, EOS-215, PTPN1/2 program) within 6-month disposition period.","Board resigned; new directors/officers from Concentra (Kevin Tang CEO, Michael Hearne CFO, etc.).","Company requests delisting from Nasdaq and intends to deregister with SEC."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-192031","json":"https://secwatch.observer/filing/0001193125-25-192031.json","markdown":"https://secwatch.observer/filing/0001193125-25-192031.md","text":"https://secwatch.observer/filing/0001193125-25-192031.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1808865/000119312525192031/0001193125-25-192031-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1808865/000119312525192031/d938711d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T09:16:25.918373+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"4df9b7d2a988bf70752978504c0a2a901510c678","claim":"iTeos Therapeutics, Inc.: Bylaws amended and restated in their entirety.","evidence_excerpt":"the Company's certificate of incorporation and bylaws were amended and restated in their entirety","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1808865/000119312525192031/0001193125-25-192031-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"bylaw amendment"}],"fact_type":"governance_change"},{"claim_id":"9b86faca4971d90a5b6edd8b05cef1e6ffe07b25","claim":"iTeos Therapeutics, Inc.: Certificate of incorporation amended and restated in its entirety.","evidence_excerpt":"the Company's certificate of incorporation and bylaws were amended and restated in their entirety","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1808865/000119312525192031/0001193125-25-192031-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"charter amendment"}],"fact_type":"governance_change"},{"claim_id":"4173616b61f92810dcc82612d7a88570ff9b14e9","claim":"iTeos Therapeutics, Inc. underwent a change of control involving Concentra Biosciences, LLC for $10.047 in cash per Share plus one non-transferable contractual contingent value right per Share (closed 2025-08-29).","evidence_excerpt":"(the “Company”) in the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission (the “SEC”) on July 21, 2025, the Company entered into an Agreement and Plan of Merger, dated as of July 18, 2025 (the “Merger Agreement”) with Concentra Biosciences, LLC, a Delaware limited liability company (“Parent”), and Concentra Merger Sub VIII, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (“Merger Sub”).","evidence_source":"SEC 8-K Item 2.01/5.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1808865/000119312525192031/0001193125-25-192031-index.htm","confidence":0.99,"family_label":"M&A Transactions","details":[{"label":"Action","value":"change of control"},{"label":"Counterparty","value":"Concentra Biosciences, LLC"},{"label":"Consideration","value":"$10.047 in cash per Share plus one non-transferable contractual contingent value right per Share"},{"label":"Closing","value":"2025-08-29"}],"fact_type":"ma_transaction"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}